Seek Returns

GMAB vs. RVMD: Genmab vs. Revolution Medicines Stock Comparison

How do Genmab (GMAB) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Genmab (GMAB) and Revolution Medicines (RVMD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Revolution Medicines (RVMD) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Genmab (GMAB) and Revolution Medicines (RVMD)
Profile ItemGMABRVMD
NameGenmab A/S American Depositary SharesRevolution Medicines, Inc.
Country/RegionDenmarkUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization32.98 billion USD41.59 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 1, 2009February 13, 2020
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

GMAB
RVMD
GSPC
Loading price history…
Genmab (GMAB) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Genmab (GMAB) and Revolution Medicines (RVMD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Genmab (GMAB) and Revolution Medicines (RVMD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Genmab (GMAB) and Revolution Medicines (RVMD)
MetricGMABRVMD
Total Return (1Y)91.17%224.80%
Total Return (3Y, Annualized)20.70%114.71%
Total Return (5Y, Annualized)3.98%43.47%

Risk Profile

Drawdown History

GMAB
RVMD
GSPC
Loading price history…
Genmab (GMAB) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Genmab (GMAB) and Revolution Medicines (RVMD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Genmab (GMAB) and Revolution Medicines (RVMD)
MetricGMABRVMD
Volatility (1Y, Annualized)45.68%68.29%
Beta (5Y)0.721.42
Max Drawdown (5Y)-61.79%-55.71%
Avg. Volume (3M)4.09M2.06M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
GMAB and RVMD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Genmab (GMAB) and Revolution Medicines (RVMD)
MetricGMABRVMD
Sharpe Ratio (1Y)1.903.23
Sortino Ratio (1Y)3.826.92

Profitability

ROE (TTM)

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Genmab (GMAB) reports 12.07%, ranking against industry peers normally.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Max
109.18%
GMAB
12.07%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-93.56%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
RVMD
-93.56%
Min
-167.77%
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Genmab (GMAB) at 16.97% retains a top-quartile share of revenue as profit, ahead of Revolution Medicines (RVMD) at 0.00%, which keeps about the industry-typical share.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Max
18.05%
GMAB
16.97%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
RVMD
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Genmab (GMAB) reports 37.15%, ranking against industry peers normally.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.15%

Max
83.12%
GMAB
37.15%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-188.88%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
RVMD
-188.88%
Min
-207.40%
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Genmab (GMAB) and Revolution Medicines (RVMD)
MetricGMABRVMD
ROE (TTM)12.07%-93.56%
ROA (TTM)8.24%-32.13%
Net Margin (TTM)16.97%0.00%
Operating Margin (TTM)37.15%-188.88%
Gross Margin (TTM)92.67%0.00%

Growth

Revenue Growth

Only one side can be read here: Genmab (GMAB) reports revenue growth of 19.19%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Genmab (GMAB) reports EPS growth of -9.23%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Genmab (GMAB) and Revolution Medicines (RVMD)
MetricGMABRVMD
Revenue Growth (YoY)19.19%--
Revenue Growth (3Y CAGR)21.23%--
EPS Growth (YoY)-9.23%--
EPS Growth (3Y CAGR)8.48%--

Financial Strength

Current Ratio (MRQ)

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while Genmab (GMAB) at 2.45 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GMAB.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GMAB
2.45
Min
0.10

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.36

Max
25.13
Q3
12.13
RVMD
8.36
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Revolution Medicines (RVMD) at 0.50 carries an industry-typical debt-to-equity mix, while Genmab (GMAB) at 0.82 uses more debt funding than most peers.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Max
1.42
GMAB
0.82
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50

Max
1.42
Q3
0.65
RVMD
0.50
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Genmab (GMAB) and Revolution Medicines (RVMD)
MetricGMABRVMD
Current Ratio (MRQ)2.458.36
Debt / Equity (MRQ)0.820.50
Net Debt / EBITDA2.45--

Dividends

Dividend Yield (TTM)

Neither Genmab (GMAB) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Genmab (GMAB) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Genmab (GMAB) and Revolution Medicines (RVMD)
MetricGMABRVMD
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Genmab (GMAB) trades at 45.84 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.84

Max
85.34
GMAB
45.84
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RVMD
--
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): RVMD does not report P/E ratio, so it has no value marker; GMAB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Genmab (GMAB) at 7.68 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.68

Max
58.18
Q3
25.77
GMAB
7.68
Median
7.30
Q1
3.01
Min
0.01

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

210.51

RVMD
210.51
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Genmab (GMAB) at 5.36 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.36

Max
13.53
Q3
6.54
GMAB
5.36
Median
3.25
Q1
1.69
Min
-5.59

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.31

RVMD
17.31
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Genmab (GMAB) vs. Revolution Medicines (RVMD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Genmab (GMAB) and Revolution Medicines (RVMD)
MetricGMABRVMD
P/E Ratio (TTM)45.84--
P/S Ratio (TTM)7.68210.51
P/B Ratio (MRQ)5.3617.31
Free Cash Flow Yield (TTM)2.59%-2.13%